BioCryst Pharmaceuticals Says Data From Open-label Extension Of APEX-2 Trial Of Orladeyo For Prophylactic Treatment Of Hereditary Angioedema In Patients 12 Years And Older Have Been Published Online By Journal Of Allergy & Clinical Immunology: In Practice
BioCryst Pharmaceuticals Says Data From Open-label Extension Of APEX-2 Trial Of Orladeyo For Prophylactic Treatment Of Hereditary Angioedema In Patients 12 Years And Older Have Been Published Online By Journal Of Allergy & Clinical Immunology: In Practice
BioCryst Pharmicals表示，《過敏與臨床免疫學雜誌：在實踐中》在線發佈了Orladeyo對12歲及以上患者進行預防性治療的 APEX-2 試驗的開放標籤延期數據
BioCryst Pharmaceuticals Says Data From Open-label Extension Of APEX-2 Trial Of Orladeyo For Prophylactic Treatment Of Hereditary Angioedema In Patients 12 Years And Older Have Been Published Online By Journal Of Allergy & Clinical Immunology: In Practice
BioCryst Pharmicals表示，《過敏與臨床免疫學雜誌：在實踐中》在線發佈了Orladeyo對12歲及以上患者進行預防性治療的 APEX-2 試驗的開放標籤延期數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。